Results of an early-stage clinical trial of two experimental vaccines against Ebola and Marburg viruses—the first to be completed in an African country—showed that they were safe and induced immune responses in healthy Ugandan adult volunteers. Developed by researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, the experimental vaccines (called DNA vaccines) were predecessors to a next-generation candidate vaccine, called the NIAID/GSK Ebola vaccine, which is currently in clinical development. The NIAID/GSK vaccine incorporates Ebola gene segments into a carrier derived from a chimpanzee adenovirus. It is being tested in several Phase 1 clinical trials around the world, with larger trials planned for early 2015.
H Kibuuka et al. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly healthy Ugandan adults: a phase 1B randomised, double-blind, placebo-controlled clinical trial. The Lancet DOI: 10.1016/S0140-6736(14)62385-0 (2014).
NIAID Director Anthony S. Fauci, M.D., and Julie E. Ledgerwood, D.O., Vaccine Research Center, NIAID, are available to comment on this research.
To schedule interviews, please contact the NIAID Office of Communications, (301) 402-1663, email@example.com.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH…Turning Discovery Into Health ®